Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune response after Human Papillomavirus vaccination in patients with autoimmune disease
2008-008169-36Phase 4Terminated
- Sponsor
- University Medical Center Utrecht
- Start
- Dec 2008
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Walrinvax in human papillomavirus infection, sponsored by University Medical Center Utrecht. Primary endpoint: Immunogenicity of HPV vaccination. Started Dec 2008; status: terminated.
02
Drugs
Walrinvax
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on 2008-008169-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008169-36.